Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $903.00 Price Target at BMO Capital Markets

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) had its target price decreased by analysts at BMO Capital Markets from $950.00 to $903.00 in a report issued on Tuesday. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ target price would suggest a potential upside of 28.88% from the company’s current price.

REGN has been the topic of several other research reports. JPMorgan Chase & Co. decreased their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. Wolfe Research started coverage on Regeneron Pharmaceuticals in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price target for the company. UBS Group cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Barclays lowered their price target on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Finally, Bank of America restated an “underperform” rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $983.65.

View Our Latest Research Report on REGN

Regeneron Pharmaceuticals Stock Performance

REGN stock traded up $33.79 during trading on Tuesday, hitting $700.64. The company had a trading volume of 541,739 shares, compared to its average volume of 873,813. The firm has a 50-day moving average price of $720.81 and a 200-day moving average price of $921.72. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The firm has a market cap of $76.99 billion, a PE ratio of 17.23, a price-to-earnings-growth ratio of 1.60 and a beta of 0.08. Regeneron Pharmaceuticals has a 1-year low of $642.00 and a 1-year high of $1,211.20.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Rakuten Securities Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 19 shares in the last quarter. FSA Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $26,000. Fairfield Financial Advisors LTD acquired a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $37,000. Truvestments Capital LLC bought a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at $39,000. Finally, Valley Wealth Managers Inc. acquired a new position in Regeneron Pharmaceuticals in the third quarter worth $49,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

(Get Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Featured Stories

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.